Article
Hematology
Karen Thudium Mueller, Stephan A. Grupp, Shannon L. Maude, John E. Levine, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, G. Doug Myers, Constantine S. Tam, Ulrich Jaeger, Stephen Ronan Foley, Peter Borchmann, Stephen J. Schuster, Edmund K. Waller, Rakesh Awasthi, Bernd Potthoff, Andy Warren, Edward R. Waldron, Fraser McBlane, Andrea Chassot-Agostinho, Theodore W. Laetsch
Summary: The study shows that humoral and cellular immune responses to tisagenlecleucel did not affect clinical outcomes in pediatric and young adult B-ALL patients and adult DLBCL patients.
Article
Hematology
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Summary: This study compares the efficacy of tisagenlecleucel with historical treatments for adults with r/r DLBCL, showing that tisagenlecleucel is associated with lower risk of death and higher overall response rate. The analysis supports improved response and overall survival in patients treated with tisagenlecleucel compared to historical treatments.
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
Mariana Bastos-Oreiro, Ana de las Heras, Maria Presa, Miguel A. Casado, Carlos Pardo, Victoria Martin-Escudero, Anna Sureda
Summary: This study assessed the cost-effectiveness and cost-utility of axi-cel versus tisa-cel in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) from the perspective of the Spanish National Health System. The analysis showed that axi-cel is highly cost-effective when compared to tisa-cel in adult patients with relapsed/refractory DLBCL in Spain.
Review
Medicine, General & Internal
Eva Gonzalez Barca
Summary: This article describes new promising therapies that are in clinical development to treat relapsed/refractory DLBCL, including CAR T-cell and monoclonal antibody therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Michael J. Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, Tomasz Wrobel, Fritz Offner, Shang-Ju Wu, Guillaume Cartron, Mark Hertzberg, Anna Sureda, David Perez-Callejo, Linda Lundberg, James Relf, Mark Dixon, Emma Clark, Kathryn Humphrey, Martin Hutchings, Marek Trney
Summary: Glofitamab therapy is effective for DLBCL, but more than half of the patients experience grade 3 or 4 adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, Francois Xavier Gros, Marie Therese Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, Rene-Olivier Casasnovas, Mohamad Mohty, Stephanie Guidez, Magalie Joris, Michael Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Benedicte Deau-Fischer, Olivier Hermine, Thomas Gastinne, Jean Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thieblemont, Roch Houot, Franck Morschhauser
Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.
Article
Immunology
Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Summary: This study evaluated the efficacy and safety of zanubrutinib plus salvage chemotherapy in R/R DLBCL patients and found that it showed high efficacy and manageable tolerability. Additionally, CAR-T cell therapy may be a priority strategy for poor responders to BTKi-based treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yvette L. Kasamon, Lauren S. L. Price, Olanrewaju O. Okusanya, Nicholas C. Richardson, Ruo-Jing Li, Lian Ma, Yu-Te Wu, Marc Theoret, Richard Pazdur, Nicole J. Gormley
Summary: Selinexor is a new potential treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma, showing promising efficacy but also significant toxicities that require close monitoring and supportive care.
Article
Oncology
Boram Lee, Hyunwoo Lee, Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Woong-Yang Park, Won Seog Kim, Young Hyeh Ko
Summary: Genetic mechanisms underlying treatment resistance in recurrent/refractory diffuse large B-cell lymphoma (rrDLBCL) were explored through targeted deep sequencing, identifying key gene mutations associated with resistance and potential candidate genes for future treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Jee H. Choe, Hisham Abdel-Azim, William Padula, Mohamed Abou-El-Enein
Summary: This study evaluated the cost-effectiveness of CAR-T cell therapies for relapsed or refractory DLBCL. The results showed that second-line axicabtagene ciloleucel and third-line or later tisagenlecleucel were cost-effective, but uncertainty remains.
Article
Hematology
Matthew J. Maurer, Lasse H. Jakobsen, Raphael Mwangi, Norbert Schmitz, Umar Farooq, Cristopher R. Flowers, Peter de Nully Brown, Carrie A. Thompson, Henrik Frederiksen, David Cunningham, Judit Jorgensen, Viola Poeschel, Grzegorz Nowakowski, John F. Seymour, Francesco Merli, Corinne Haioun, Herve Ghesquieres, Marita Ziepert, Herve Tilly, Gilles Salles, Qian Shi, Tarec C. El-Galaly, Thomas M. Habermann
Summary: In DLBCL patients, disease progression after frontline therapy has a significant impact on post-progression survival. A prognostic model incorporating two key variables was developed and showed good performance in both the discovery and validation sets.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Max S. Topp, Herbert Eradat, Axel Florschuetz, Andreas Hochhaus, Tomasz Wrobel, Jan Walewski, Wanda Knopinska-Posluszny, Abraham S. Kanate, Ewa Lech-Maranda, Uta Brunnberg, Surya Chitra, Tina G. Nielsen, Gila Sellam, Mahesh Shivhare, Izidore S. Lossos
Summary: This study evaluated the efficacy and safety of two anti-CD20-based triplet combinations for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. The results showed limited efficacy and safety issues with G-atezo-pola in patients with relapsed diffuse large B-cell lymphoma, indicating no further development is planned.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Immunology
Eva Gonzalez Barca
Summary: Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. Standard first-line therapy is R-CHOP, while salvage high-dose chemotherapy with autologous stem cell transplant is the standard second-line treatment. However, not all patients are eligible for these treatments, and IgG-like bispecific antibodies (BsAbs) have shown promising efficacy in B-cell lymphomas by targeting CD20 on B cells and engaging T cells via CD3. BsAbs have a favorable toxicity profile and are being studied in new trials to confirm their efficacy and explore their use in different lines of therapy or in combination with other drugs.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Changju Qu, Rui Zou, Peng Wang, Qian Zhu, Liqing Kang, Nana Ping, Fan Xia, Hailing Liu, Danqing Kong, Lei Yu, Depei Wu, Zhengming Jin
Summary: This study demonstrates that CD19/CD22 dual-targeted CAR-T therapy, under a decitabine-containing lymphodepletion regimen, may be a safe and potent effective approach for patients with relapsed/refractory DLBCL.
FRONTIERS IN IMMUNOLOGY
(2022)
